Now showing items 1-2 of 2
The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study
There is a growing public health need for effective preventive interventions against dengue, and a safe, effective and affordable dengue vaccine against the four serotypes would be a significant achievement for disease ...
Ethics of a partially effective dengue vaccine: Lessons from the Philippines
Dengvaxia, a chimeric yellow fever tetravalent dengue vaccine developed by SanofiPasteur is widely licensed in dengue-endemic countries. In a large cohort study Dengvaxia was found to partially protect children who had ...